Particularly, TXNIP reduction occurs in both K562G and K562R cells, indicating TXNIP-mediated glucose metabolic reprogramming is an early event during the resistance of CML to imatinib. This evidence concerns the gene TXNIP and chronic myelogenous leukemia, BCR-ABL1 positive.